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Cardiovascular toxicity is the most common cause of fatality in the first 24 hours of poisoning with aluminium phosphide 
(AlP). Most often manifesting itself in cardiac dysrhythmias. The aim of this study was to evaluate the benefits of 
amiodarone prophylaxis against cardiac dysrhythmia in 46 patients with acute AlP poisoning. They were divided in two 
groups of 23: one receiving amiodarone and the other not (control). The treatment group received amiodarone prophylaxis 
in the initial intravenous bolus dose of 150 mg, followed by a drip of 1 mg/min for six hours and then of 0.5 mg/min for 
eighteen hours. Both groups were Holter-monitored for 24 hours since admission. Save for amiodarone, both groups 
received the same standard treatment. Amiodarone had a significant beneficial effect in reducing the frequency of ST-
segment elevation and ventricular fibrillation plus atrial fibrillation (P=0.02 and P=0.01, respectively), but the groups did 
not differ significantly in mortality (9 vs 11 patients, respectively). The mean time between ICU admission and death 
(survival time) was significantly longer in the treatment group (22 vs 10 h, respectively; P=0.03). Regardless its obvious 
limitations, our study suggests that even though amiodarone alone did not reduce mortality, it may provide enough time 
for antioxidant therapy to tip the balance in favour of survival and we therefore advocate its prophylactic use within the 
first 24 h of AlP poisoning.
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Aluminium phosphide (AlP) is used in agriculture due 
to low cost and high efficacy as a fumigant pesticide. Acute 
AlP poisoning is mainly reported in Asian countries like India 
and Iran (1-3) and is the most common cause of death among 
pesticides, with a mortality rate of 31% to 77% (2-6).
Signs and symptoms of acute AlP poisoning include 
gastrointestinal, cardiovascular, hepatic, renal, and 
neurologic (1). Most of the deaths occur within the first 24 
hours after ingestion due to cardiovascular involvement, 
dysrhythmias such as ventricular tachycardia (VT), 
ventricular fibrillation (VF), supra-ventricular tachycardia 
(SVT), and atrial flutter and fibrillation (AF) in particular 
(7-10).
Amiodarone is an antidysrhythmic used to treat SVT 
and ventricular tachydysrhythmia, by blocking repolarisation 
and prolonging the refractory period of the myocardium, 
which prevents tachydysrhythmia. It is associated with 
improved survival in non-ischaemic cardiomyopathy but 
not in post-myocardial infarction, yet its use in post-
myocardial infarction and congestive heart failure patients 
is safe (11, 12). Amiodarone also improves survival in 
patients with AF by effectively converting AF to sinus 
rhythm and maintaining it after conversion (12).
For all these reasons, the aim of this study was to 




This was a prospective, randomised, controlled, open 
label clinical trial in patients with acute AlP poisoning. The 
study included 46 patients older than 12 years admitted to 
the Medical Toxicology Intensive Care Unit (MT ICU) of 
the Loghman Hakim Hospital Poison Center, Tehran, Iran 
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over six months. Patients with the history of diabetes 
mellitus, cardiovascular, respiratory, renal, and hepatic 
failure, substance abuse, co-ingestion, advanced medical 
management for poisoning, and antidysrhythmic therapy 
started elsewhere before admission were excluded from the 
study.
The diagnosis was based on the history of exposure, 
clinical manifestations, and positive silver nitrate test on 
exhaled breath or stomach content samples. The study was 
approved by the Ethics Committee of the Shahid Beheshti 
University of Medical Sciences in Tehran and observed the 
Declaration of Helsinki.
Treatment protocol
The treatment started with gastric decontamination in 
the Emergency Department, followed by immediate 
admission to the ICU and management based on the same 
standard protocol for all patients (4–6 g of magnesium 
sulphate and 4 g of calcium gluconate by intravenous (IV) 
infusion daily and adequate hydration), except for 
amiodarone treatment. IV infusion of 10 µg/min 
norepinephrine was administered as required. All the 
patients were treated under the supervision of the same 
physicians and nurses.
The patients were randomised in two groups: those with 
even file number were assigned to the treatment group 
receiving amiodarone prophylaxis (n=23) and those with 
the odd file number were assigned to control (not receiving 
amiodarone) (n=23).
The initial loading dose of 150 mg was given as IV 
bolus, followed by IV infusions of 1 mg/min for six hours 
and then of 0.5 mg/min for another 18 hours, as described 
elsewhere (13). Both groups were monitored with a 24-hour 
Holter from admission to the ICU or until the time of death 
if it occurred within the first 24 h. Holter records were then 
given to a cardiologist blind to the treatment and control 
groups for interpretation. All the patients were followed up 
until discharge from the hospital or death.
Patient information about sex, age, cause of poisoning, 
ingested AlP dose, time between ingestion and ICU 
admission, clinical manifestations and paraclinical findings 
on admission time, duration of hospitalisation, and outcome 
were taken from the patients’ medical files. All information 
was kept confidential during the study.
Statistical analysis
The data were expressed as mean ± standard deviation 
(SD), frequency, and ratio and analysed with SPSS version 
16 (SPSS Inc., Chicago, IL, USA). Qualitative variables 
were compared with the chi-square test, and quantitative 
variables were tested for normality of distribution with the 
Kolmogorov-Smirnov test. Variables with normal 
distribution were further tested with Student’s t-test and 
others with the Mann-Whitney U-test. P values of 0.05 or 
less were considered statistically significant.
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Figure 1 Comparison of survival time between the treatment and control group; + – censored observations (patients discharged from 
the ICU, with unknown survival time)
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RESULTS
In 45 of the 46 cases poisoning was intentional, and 20 
patients died (ratio 0.435). Table 1 shows the demographic, 
clinical and laboratory data for both groups on admission 
to the ICU.
Table 2 compares the frequencies of dysrhythmias 
registered by the Holter between the groups. Amiodarone 
significantly lowered the occurrence of ST-segment 
elevation and VF+AF.
The need for the administration of vasopressor 
norepinephrine and mortality did not significantly differ 
between the treatment and control group [12 vs 13 patients 
(P=1) for norepinephrine and 9 vs 11 patients for mortality 
(P=0.8), respectively].
Median time elapsed between ICU admission and death 
(survival time) was 23 h (range: 16–28) in the treatment 
group and 10 h (range: 6-14) in the control group (P<0.001) 
(Figure 1).
DISCUSSION
To the best of our knowledge there are only two studies 
on IV administration of amiodarone in acute AlP poisoning, 
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Table 1 Demographic, clinical, and laboratory data of patients with acute AlP poisoning admitted to ICU
Parameter
(normal range)








Mean ± SD 
(range)
Sex
Women 14 (0.609) 13 (0.565)
0.8
Men 9 (0.391) 10 (0.435)
Age (year) 22.7±6.1 (15–36) 25.7±10.6 (13–52) 0.5
Number of ingested AlP tablets 2±2 (0.25–8) 1.2±0.7 (0.25–3) 0.08
Time between AlP ingestion and ICU 
admission (hours) 5.6±5.4 (1.2–20) 5.3±5.8 (0.45–18.1) 0.2
Abdominal pain
No 8 (0.348) 7 (0.304)
0.8
Yes 15 (0.652) 16 (0.696)
Vomiting
No 2 (0.87) 3 (0.13)
0.6
Yes 21 (0.913) 20 (0.87)
Chest Pain
No 12 (0.522) 11 (0.478)
0.8
Yes 11 (0.478) 12 (0.522)
Dyspnoea
No 15 (0.652) 16 (0.696)
0.8
Yes 8 (0.378) 7 (0.304)
Loss of consciousness
No 22 (0.957) 21 (0.914)
1
Yes 1 (0.43) 2 (0.86)
Systolic blood pressure (120–140 mmHg) 103±18.9 (72–150) 94.5±19.5 (63–139) 0.3
Diastolic blood pressure (70–90 mmHg) 60.7±13 (40–86) 55.5±13.9 (35–88) 0.2
Pulse rate (60–100/min) 108±17.9 (70–133) 97.1±18.6 (61–135) 0.05
Respiratory rate (12–20/min) 15.8±10.3 (0–30) 19.3±6 (0–31) 0.4
Need for intubation and mechanical 
ventilation
No 19 (0.826) 21 (0.913)
0.7
Yes 4 (0.174) 2 (0.087)
Blood chemistry
pH (7.35–7.45) 7.34±0.15 (6.90–7.35) 7.37±0.12 (7.08–7.57) 0.7
PCO2 (35–45 mmHg) 35 ±14.3 (19–87) 30.6±7.2 (19.6–45.9) 0.6
Serum HCO3 (22–26 mEq/L) 17.6±5.4 (9.4–29) 18.5±5.9 (10.6–32.8) 0.6
O2 saturation (%) 90.3±5.7 (77–98) 92.3±4.2 (85–98) 0.3
Sodium (135–145 mEq/L) 141.5±4.5 (131–148) 142.1±3.9 (136–150) 0.6
Potassium (3.5–5 mEq/L) 3.8±0.4 (3–5) 3.9±0.3 (3.5–4.4) 0.4
Calcium (8.4–10.2 mg/dL) 8.9±0.7 (8–10.1) 9.1±0.8 (8–10.5) 0.4
Magnesium (1.9–2.5 mg/dL) 2.3±0.5 (1.6–3) 2.1±0.4 (1.4–2.6) 0.5
Blood glucose (70–110 mg/dL) 103±18.9 (72–150) 94.5±19.5 (63–139) 0.1
SD=standard deviation
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Table 2 The frequencies of dysrhythmias monitored by 24-hour Holter in patients with acute AlP poisoning
Type of dysrhythmia Treatment group(n=23)
Control group
(n=23) P value
Sinus bradycardia 1 1 1
First-degree atrioventricular block 0 1 0.3
Second-degree atrioventricular block
(Mobitz type II) 1 0 0.3
Atrial premature contraction (APC) 13 9 0.2
Sinus tachycardia 9 7 0.5
Atrial fibrillation (AF) 3 8 0.08
Junctional rhythm 2 1 0.5
Idioventricular rhythm 4 3 0.6
Ventricular premature contraction (VPC) 10 13 0.3
Ventricular tachycardia (VT) 9 6 0.5
Ventricular fibrillation (VF) 1 5 0.3
Left bundle branch block (LBBB) 3 1 0.3
Right Bundle Branch Block (RBBB) 7 3 0.2
ST-segment elevation 1 7 0.02*
ST-segment depression 2 3 0.6
VF+AF 3 11 0.01*
VT and VF and AF 8 13 0.1
Asystole following AF 2 7 0.06
*Statistically significant difference between the two groups (P<0.05)
and one reported no VT response to treatment (14) and the 
other reported very limited beneficial effects (15). Even 
though amiodarone prophylaxis in our study significantly 
decreased the occurrence of AF+VF and ST-segment 
elevation and significantly increased survival time, it did 
not reduce mortality. However, interpretation of our results 
is quite limited by the small sample.
Another limitation of our study is that we did not 
observe or treat myocardial oxidative damage, whereas 
other studies showed significant beneficial effects of 
antioxidants against cardiovascular toxicity (16–18). Future 
studies should therefore combine amiodarone and 
antioxidant treatment.
Even though amiodarone alone did not reduce mortality, 
it may provide enough time for antioxidant therapy to tip 
the balance in favour of survival and we therefore advocate 
its prophylactic use within the first 24 h of AlP poisoning.
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Djelotvornost amiodarona u profilaksi srčane disritmije uzrokovane akutnim otrovanjem aluminijevim fosfidom
Najčešći uzrok smrti u prva 24 sata od otrovanja aluminijevim fosfidom (AlP) jesu njegovi toksični učinci na srce i 
krvožilje. Oni se obično manifestiraju srčanim disritmijama. Cilj je ovoga ispitivanja bio procijeniti blagotvorne učinke 
amiodarona u profilaksi srčane disritmije u 46 bolesnika primljenih na intenzivnu njegu s otrovanjem AlP-om. Bolesnici 
su podijeljeni u dvije skupine od 23 ispitanika. Jedna je primala amiodaron, a druga (kontrolna) nije. Ostalo liječenje bilo 
je standardno i identično u objema skupinama. Amiodaronska se je profilaksa sastojala od udarne intravenske bolusne 
doze od 150 mg, nakon čega je uslijedila infuzija u dozi od 1 mg/min prvih šest sati, a zatim od 0,5 mg/min sljedećih 
osamnaest sati. Obje su skupine od prijama na intenzivnu njegu bile nadzirane 24-satnim holterom. Amiodaron je iskazao 
značajnu djelotvornost u smanjenju učestalosti povišenoga ST-segmenta odnosno ventrikulske i atrijske fibrilacije (P=0,02 
odnosno P=0,01), ali nije značajno smanjio smrtnost (9 bolesnika u skupini na amiodaronu odnosno 11 u kontrolnoj 
skupini). Srednje vrijeme od prijama na intenzivnu njegu do smrti (vrijeme preživljenja), međutim, značajno se produžilo 
u skupini na amiodaronu (22 h prema 10 h u kontrolnoj skupini; P=0,03). Unatoč jasnim ograničenjima, napose zbog 
premaloga uzorka, ovo ispitivanje upućuje na to da amiodaron može dovoljno produžiti vrijeme preživljenja i time dati 
dovoljno vremena antioksidacijskom liječenju da spasi život te iz tog razloga preporučujemo njegovu profilaktičku 
primjenu u prva 24 sata od otrovanja AlP-om.
KLJUČNE RIJEČI: AlP; antidisritmici; atrijska fibrilacija; EKG; holter; ST-segment; toksičnost; ventrikulska fibrilacija
